查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1625473

去势抵抗性前列腺癌市场、规模、占有率、趋势、行业分析报告（按疗法和地区）- 市场预测，2025-2034 年

Castrate-Resistant Prostate Cancer Market Size, Share, Trends, Industry Analysis Report: By Therapy and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 128 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的一项新研究，去势抵抗性前列腺癌 (CRPC) 市场预计到 2034 年将达到 297.9 亿美元。该研究报告对当前市场动态提供了详细的见解，并对未来市场成长进行了分析。

去势抵抗性前列腺癌市场的成长是由发病率的上升所推动的，尤其是在老龄化人口中。前列腺癌通常会发展到较晚期、难以治疗的阶段。这促使对有效治疗的需求增加，从而推动了标靶治疗和精准肿瘤学的进步。赛诺菲公司、强生公司、辉瑞公司、拜耳公司和安斯泰来製药公司等主要参与者正在透过先进的产品和持续的创新来推动这个市场。随着主要参与者专注于雄激素受体抑制剂、免疫疗法和其他有针对性的方法等新型治疗方法，CRPC 市场规模正在扩大。这些进步正在帮助提供全面 CRPC 治疗方案的公司获得市场占有率。

去势抵抗性前列腺癌的市场趋势表明，人们正转向个人化医疗和联合疗法，以提供更高的疗效和更少的副作用。北美凭藉其强大的医疗保健基础设施、高度的知名度和成熟的医学研究机构在全球市场占据主导地位。然而，由于前列腺癌盛行率上升、医疗保健机会改善和监管对新疗法的支持，预计亚太地区将呈现最高的复合年增长率。这些地区去势抵抗性前列腺癌 (CRPC) 市场的成长反映了全球对肿瘤学研究和治疗的投资不断增加的广泛趋势。此外，随着各公司寻求扩大其产品线和地理覆盖范围，合作和併购活动也十分活跃，进一步推动了去势抵抗性前列腺癌市场的扩张。

去势抵抗性前列腺癌市场报告重点

由于荷尔蒙疗法透过降低雄性激素水平来减缓病情进展的有效性已被证实，因此荷尔蒙疗法领域将在 2024 年占据去势抵抗性前列腺癌市场的最大占有率。

预计免疫治疗领域在预测期内的复合年增长率将达到1.5%，因为它提供了一种有前景且侵入性较小的治疗选择，能够利用人体的免疫系统专门针对和攻击前列腺癌细胞。

由于其先进的医疗保健基础设施和前列腺癌的高盛行率，北美在 2024 年占据了去势抵抗性前列腺癌市场的主导占有率。

由于人们对先进治疗方案的认识不断提高以及政府在癌症治疗方面的支持措施，预计亚太市场在预测期内将出现显着增长。

全球市场的主要参与者是赛诺菲公司、强生公司、辉瑞公司、拜耳公司、雅培实验室、葛兰素史克公司、西北生物治疗公司、Active Biotech AB、安斯泰来製药公司和Dendreon 公司。

目录

第 1 章简介

第 2 章执行摘要

第 3 章 研究方法

第 4 章全球去势抵抗性前列腺癌市场洞察
  • 市场概况
  • 去势抵抗性前列腺癌市场动态
    • 推动因素和机遇
      • 摄护腺癌发生率不断上升
      • 老年人口增加
    • 阻碍因素和课题
      • 末期病患的治疗选择有限
  • PESTEL 分析
  • 去势抵抗性摄护腺癌的市场趋势
  • 价值链分析
  • COVID-19 影响分析

第5章 全球去势抵抗性前列腺癌市场（依疗法划分）

  • 主要发现
  • 简介
  • 化疗
  • 荷尔蒙疗法
  • 免疫疗法
  • 放射治疗

第6章全球去势抗性前列腺癌市场（按地区）

  • 主要发现
  • 简介
      去势抵抗性前列腺癌市场评估：地区，2020 年至 2034 年
  • 北美洲
    • 北美，依疗法分类，2020 年至 2034 年
    • 美国
    • 加拿大
  • 欧洲
      欧洲：依疗法分类，2020 年至 2034 年
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 其他欧洲国家
    亚太地区
      亚太地区，依疗法分类，2020 年至 2034 年
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲
    • 中东和非洲：依疗法分类，2020 年至 2034 年
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东和非洲地区
  • 拉丁美洲
    • 拉丁美洲，依疗法分类，2020 年至 2034 年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他拉丁美洲国家

第 7 章 竞争格局

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协定/揭露

第 8 章 公司简介

  • Sanofi S.A.
  • Johnson & Johnson
  • Pfizer, Inc.
  • Bayer AG
  • Abbott Laboratories
  • GlaxoSmithKline PLC
  • Northwest Biotherapeutics, Inc.
  • Active Biotech AB
  • Astellas Pharma, Inc.
  • Dendreon Corporation
Product Code: PM5332

The castrate-resistant prostate cancer (CRPC) market size is expected to reach USD 29.79 billion by 2034, according to a new study by Polaris Market Research. The report "Castrate-Resistant Prostate Cancer Market Share, Size, Trends, Industry Analysis Report: By Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, and Radiotherapy) and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The castrate-resistant prostate cancer market growth is attributed to increasing incidence rates, especially among aging populations. Prostate cancer often progresses to a more advanced, treatment-resistant stage. Thus, the demand for effective therapies has grown, leading to advancements in targeted treatments and precision oncology. Key players such as Sanofi S.A.; Johnson & Johnson; Pfizer, Inc.; Bayer AG; and Astellas Pharma, Inc. drive this market with leading products and continued innovation. The CRPC market size has expanded as major companies focus on novel therapies such as androgen receptor inhibitors, immunotherapies, and other targeted approaches. Such advancements have contributed to increased market share among companies offering comprehensive CRPC treatment options.

The castrate-resistant prostate cancer market trends indicate a shift toward personalized medicine and combination therapies that offer enhanced efficacy with fewer side effects. North America dominates the global market due to robust healthcare infrastructure, high awareness, and established medical research institutions. However, Asia Pacific is expected to witness the highest CAGR due to rising prostate cancer incidence, improved healthcare access, and regulatory support for new treatments. The castrate-resistant prostate cancer market (CRPC) market growth in these regions reflects a broader global trend of increasing investments in oncology research and treatment. Additionally, partnerships, and mergers and acquisitions are prevalent, as companies seek to expand their product pipelines and geographic reach, further fueling the castrate-resistant prostate cancer market expansion.

Castrate-Resistant Prostate Cancer Market Report Highlights

In terms of therapy, in 2024, the hormonal therapy segment accounted for the largest share of the castrate-resistant prostate cancer market due to its proven effectiveness in slowing disease progression by reducing androgen levels.

The immunotherapy segment is expected to witness the highest CAGR during the forecast period due to its ability to harness the body's immune system to specifically target and attack prostate cancer cells, offering a promising and less invasive treatment option.

In 2024, North America dominated the castrate-resistant prostate cancer market share due to its advanced healthcare infrastructure and high prevalence of prostate cancer.

The Asia Pacific market is expected to witness significant growth during the forecast period due to the growing awareness of advanced treatment options and supportive government initiatives in cancer care.

A few global key market players are Sanofi S.A.; Johnson and Johnson; Pfizer, Inc.; Bayer AG; Abbott Laboratories; GlaxoSmithKline PLC; Northwest Biotherapeutics, Inc.; Active Biotech AB; Astellas Pharma, Inc; and Dendreon Corporation.

Polaris Market Research has segmented the castrate-resistant prostate cancer market report on the basis of therapy, and region:

By Therapy Outlook (Revenue, USD Billion; 2020-2034)

  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy
  • Radiotherapy

By Regional Outlook (Revenue, USD Billion; 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Castrate-resistant Prostate Cancer Market Insights

  • 4.1. Castrate-resistant Prostate Cancer Market - Market Snapshot
  • 4.2. Castrate-resistant Prostate Cancer Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Incidence of Prostate Cancer
      • 4.2.1.2. Growing Geriatric Population
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Limited Treatment Options for Late-stage Disease
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Castrate-resistant Prostate Cancer Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Castrate-resistant Prostate Cancer Market, by Therapy

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 5.3. Chemotherapy
    • 5.3.1. Global Castrate-resistant Prostate Cancer Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
  • 5.4. Hormonal Therapy
    • 5.4.1. Global Castrate-resistant Prostate Cancer Market, by Hormonal Therapy, by Region, 2020-2034 (USD Billion)
  • 5.5. Immunotherapy
    • 5.5.1. Global Castrate-resistant Prostate Cancer Market, by Immunotherapy, by Region, 2020-2034 (USD Billion)
  • 5.6. Radiotherapy
    • 5.6.1. Global Castrate-resistant Prostate Cancer Market, by Radiotherapy, by Region, 2020-2034 (USD Billion)

6. Global Castrate-resistant Prostate Cancer Market, by Geography

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Castrate-resistant Prostate Cancer Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 6.3. Castrate-resistant Prostate Cancer Market - North America
    • 6.3.1. North America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.3.2. Castrate-resistant Prostate Cancer Market - U.S.
      • 6.3.2.1. U.S.: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.3.3. Castrate-resistant Prostate Cancer Market - Canada
      • 6.3.3.1. Canada: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.4. Castrate-resistant Prostate Cancer Market - Europe
    • 6.4.1. Europe: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.2. Castrate-resistant Prostate Cancer Market - UK
      • 6.4.2.1. UK: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.3. Castrate-resistant Prostate Cancer Market - France
      • 6.4.3.1. France: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.4. Castrate-resistant Prostate Cancer Market - Germany
      • 6.4.4.1. Germany: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.5. Castrate-resistant Prostate Cancer Market - Italy
      • 6.4.5.1. Italy: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.6. Castrate-resistant Prostate Cancer Market - Spain
      • 6.4.6.1. Spain: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.7. Castrate-resistant Prostate Cancer Market - Netherlands
      • 6.4.7.1. Netherlands: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.8. Castrate-resistant Prostate Cancer Market - Russia
      • 6.4.8.1. Russia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.9. Castrate-resistant Prostate Cancer Market - Rest of Europe
      • 6.4.9.1. Rest of Europe: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.5. Castrate-resistant Prostate Cancer Market - Asia Pacific
    • 6.5.1. Asia Pacific: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.2. Castrate-resistant Prostate Cancer Market - China
      • 6.5.2.1. China: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.3. Castrate-resistant Prostate Cancer Market - India
      • 6.5.3.1. India: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.4. Castrate-resistant Prostate Cancer Market - Malaysia
      • 6.5.4.1. Malaysia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.5. Castrate-resistant Prostate Cancer Market - Japan
      • 6.5.5.1. Japan: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.6. Castrate-resistant Prostate Cancer Market - Indonesia
      • 6.5.6.1. Indonesia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.7. Castrate-resistant Prostate Cancer Market - South Korea
      • 6.5.7.1. South Korea: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.8. Castrate-resistant Prostate Cancer Market - Australia
      • 6.5.8.1. Australia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.9. Castrate-resistant Prostate Cancer Market - Rest of Asia Pacific
      • 6.5.9.1. Rest of Asia Pacific: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.6. Castrate-resistant Prostate Cancer Market - Middle East & Africa
    • 6.6.1. Middle East & Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.6.2. Castrate-resistant Prostate Cancer Market - Saudi Arabia
      • 6.6.2.1. Saudi Arabia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.6.3. Castrate-resistant Prostate Cancer Market - UAE
      • 6.6.3.1. UAE: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.6.4. Castrate-resistant Prostate Cancer Market - Israel
      • 6.6.4.1. Israel: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.6.5. Castrate-resistant Prostate Cancer Market - South Africa
      • 6.6.5.1. South Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.6.6. Castrate-resistant Prostate Cancer Market - Rest of Middle East & Africa
      • 6.6.6.1. Rest of Middle East & Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.7. Castrate-resistant Prostate Cancer Market - Latin America
    • 6.7.1. Latin America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.7.2. Castrate-resistant Prostate Cancer Market - Mexico
      • 6.7.2.1. Mexico: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.7.3. Castrate-resistant Prostate Cancer Market - Brazil
      • 6.7.3.1. Brazil: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.7.4. Castrate-resistant Prostate Cancer Market - Argentina
      • 6.7.4.1. Argentina: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.7.5. Castrate-resistant Prostate Cancer Market - Rest of Latin America
      • 6.7.5.1. Rest of Latin America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

7. Competitive Landscape

  • 7.1. Expansion and Acquisition Analysis
    • 7.1.1. Expansion
    • 7.1.2. Acquisitions
  • 7.2. Partnerships/Collaborations/Agreements/Exhibitions

8. Company Profiles

  • 8.1. Sanofi S.A.
    • 8.1.1. Company Overview
    • 8.1.2. Financial Performance
    • 8.1.3. Product Benchmarking
    • 8.1.4. Recent Development
  • 8.2. Johnson & Johnson
    • 8.2.1. Company Overview
    • 8.2.2. Financial Performance
    • 8.2.3. Product Benchmarking
    • 8.2.4. Recent Development
  • 8.3. Pfizer, Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Financial Performance
    • 8.3.3. Product Benchmarking
    • 8.3.4. Recent Development
  • 8.4. Bayer AG
    • 8.4.1. Company Overview
    • 8.4.2. Financial Performance
    • 8.4.3. Product Benchmarking
    • 8.4.4. Recent Development
  • 8.5. Abbott Laboratories
    • 8.5.1. Company Overview
    • 8.5.2. Financial Performance
    • 8.5.3. Product Benchmarking
    • 8.5.4. Recent Development
  • 8.6. GlaxoSmithKline PLC
    • 8.6.1. Company Overview
    • 8.6.2. Financial Performance
    • 8.6.3. Product Benchmarking
    • 8.6.4. Recent Development
  • 8.7. Northwest Biotherapeutics, Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Financial Performance
    • 8.7.3. Product Benchmarking
    • 8.7.4. Recent Development
  • 8.8. Active Biotech AB
    • 8.8.1. Company Overview
    • 8.8.2. Financial Performance
    • 8.8.3. Product Benchmarking
    • 8.8.4. Recent Development
  • 8.9. Astellas Pharma, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Financial Performance
    • 8.9.3. Product Benchmarking
    • 8.9.4. Recent Development
  • 8.10. Dendreon Corporation
    • 8.10.1. Company Overview
    • 8.10.2. Financial Performance
    • 8.10.3. Product Benchmarking
    • 8.10.4. Recent Development

List of Tables:

Table 1 Global Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 2 North America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 3 U.S.: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 4 Canada: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 5 Europe: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 6 UK: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 7 France: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 8 Germany: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 9 Italy: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 10 Spain: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 11 Netherlands: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 12 Russia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 13 Rest of Europe: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 14 Asia Pacific: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 15 China: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 16 India: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 17 Malaysia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 18 Japan: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 19 Indonesia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 20 South Korea: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 21 Australia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 22 Rest of Asia Pacific: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 23 Middle East & Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 24 Saudi Arabia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 25 UAE: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 26 Israel: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 27 South Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 28 Rest of Middle East & Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 29 Latin America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 30 Mexico: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 31 Brazil: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 32 Argentina: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 33 Rest of Latin America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

List of Figures:

Figure 1. Global Castrate-resistant Prostate Cancer Market, 2020-2034 (USD Billion)

Figure 2. Integrated Ecosystem

Figure 3. Research Methodology: Top-Down & Bottom-Up Price

Figure 4. Market by Geography

Figure 5. Porter's Five Forces

Figure 6. Market by Therapy

Figure 7. Global Castrate-resistant Prostate Cancer Market, by Therapy, 2024 & 2034 (USD Billion)